- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
**Financial Performance:** SMS Pharmaceuticals reported an 18% year-on-year increase in revenues, reaching ₹196.75 crores for the quarter, driven by strong volume growth. Sequentially, revenues rose 20%, and total revenues for H1 FY25 reached ₹361.2 crores, also a 20% increase compared to the prior year. Gross margins for Q2 stood at 30%, reflecting some decline due to rising raw material costs, with stable gross margins of 32% for H1. EBITDA margins were consistent at 16% for Q2 and 18% for H1. Profit after tax (PAT) improved to ₹14.1 crores in Q2, a 20% year-on-year increase, with PAT margins maintained at 7%. H1 PAT grew 45% to ₹30.58 crores, boosting margins to 8.5%.
**Future Outlook and Growth Drivers:** Management emphasized their ongoing strategy focused on diversifying their API portfolio and expanding market presence. The anticipated completion of a ₹150 crore CAPEX for backward integration aims to enhance margins by reducing dependency on external suppliers.
**Order Book and Operational Updates:** The company received EDQM certification for its Vizag facility, enabling it to supply ibuprofen to Europe. Capacity expansion and vertical integration projects are on track for completion by Q4 FY25.
**Analyst Q&A Insights:** Analysts inquired about CAPEX’s role in profitability and growth. Management indicated that improved vertical integration would bolster margins by 5-8%. Questions on product lines and pricing pressures were addressed; Ranolazine’s market remains flat with significant pricing erosion.
**Strategic Focus Areas:** Strong emphasis was placed on operational efficiency and innovation, with management conveying confidence amid cost pressures and market volatility.
**Investor Insight:** Given the solid revenue growth and proactive measures to enhance margins and operational efficiencies, the company appears positioned for sustained growth. The strategic focus on backward integration alongside solid financial performance suggests a positive outlook moving forward.